n-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide and Peripheral-Nervous-System-Diseases

n-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide has been researched along with Peripheral-Nervous-System-Diseases* in 1 studies

Trials

1 trial(s) available for n-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide and Peripheral-Nervous-System-Diseases

Article	Year
Momelotinib treatment-emergent neuropathy: prevalence, risk factors and outcome in 100 patients with myelofibrosis. British journal of haematology, 2015, Volume: 169, Issue:1 Momelotinib (a JAK1 and JAK2 inhibitor) induces both anaemia and spleen responses in myelofibrosis (MF). Momelotinib treatment-emergent peripheral neuropathy (TE-PN) was documented in 44 (44%) of 100 MF patients treated at our institution; median time of TE-PN onset was 32 weeks and duration 11 months. Improvement after drug dose reduction or discontinuation was documented in only two patients. TE-PN was significantly associated with treatment response (P = 0·02) and longer survival (P = 0·048) but significance was lost during multivariate analysis that included treatment duration. TE-PN did not correlate with initial or maximum momelotinib dose or previous treatment with JAK inhibitor or thalidomide. Topics: Adult; Aged; Aged, 80 and over; Benzamides; Female; Humans; Janus Kinase 1; Janus Kinase 2; Male; Middle Aged; Peripheral Nervous System Diseases; Prevalence; Primary Myelofibrosis; Pyrimidines; Risk Factors	2015

Article

Year

Momelotinib treatment-emergent neuropathy: prevalence, risk factors and outcome in 100 patients with myelofibrosis.

British journal of haematology, 2015, Volume: 169, Issue:1

Momelotinib (a JAK1 and JAK2 inhibitor) induces both anaemia and spleen responses in myelofibrosis (MF). Momelotinib treatment-emergent peripheral neuropathy (TE-PN) was documented in 44 (44%) of 100 MF patients treated at our institution; median time of TE-PN onset was 32 weeks and duration 11 months. Improvement after drug dose reduction or discontinuation was documented in only two patients. TE-PN was significantly associated with treatment response (P = 0·02) and longer survival (P = 0·048) but significance was lost during multivariate analysis that included treatment duration. TE-PN did not correlate with initial or maximum momelotinib dose or previous treatment with JAK inhibitor or thalidomide.

Topics: Adult; Aged; Aged, 80 and over; Benzamides; Female; Humans; Janus Kinase 1; Janus Kinase 2; Male; Middle Aged; Peripheral Nervous System Diseases; Prevalence; Primary Myelofibrosis; Pyrimidines; Risk Factors

2015